| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1157ee8e39ba4cad70bda99b8e68cb93 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-80
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K17-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4721
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-385
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-78 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-385 |
| filingDate |
2010-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fa9ed9172ad1862741150ca37692859e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_109c94f0bcd69f372c2d289786124a55 |
| publicationDate |
2011-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2783969-A1 |
| titleOfInvention |
A novel vaccine that targets tumor vessels as an efficient tool in tumor therapy |
| abstract |
The invention relates to a composition for the treatment of various cancers. The composition is a vaccine containing sequences of EDB, EDA, annexin A1, endosialin, C domain of tenascin C or magic roundabout (MR) or fragments thereof as single or in a combination coupled to one or several heterologous foreign carrier molecules. The vaccine will produce antibodies that are directed against self proteins which are preferentially expressed in and around tumor vessels. The vaccine is preferably administrated together with an adjuvant. |
| priorityDate |
2009-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |